Second, we need to improve our understanding of the cellular circumstances beyond BRCAness [134] under which targeting of RAD52 can lead to cancer cell death and when RAD52 inhibition can be combined with other inhibitors or DNA damaging chemotherapy. This evidence concerns the gene RAD52 and cancer.